IMPL News and Press, Impel Pharmaceuticals Inc. From 05/10/23

2023-05-10 08:35:57 ET Impel Pharmaceuticals ( NASDAQ: IMPL ) appoints Michael W. Kalb, CPA, as CFO, effective May 10, 2023. Mr. Kalb has more than 30 years of experience in the pharmaceutical and financial service industries. Prior to joining Impel Pharmaceuticals, h...

SEATTLE, May 10, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ: IMPL), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today announced the appointment of Michael W. Kalb, CPA...

SEATTLE, May 05, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced it will host a live webcast on Friday, May 12, 2023,...

New Analysis Indicates No Drug-Drug Interactions (DDIs) of Clinical Concern are Predicted When Recommended Doses of Trudhesa and Gepants are Co-Administered Additional Analyses from the STOP 301 Trial Show Concomitant Use of Trudhesa with Triptans and Preventative CGRP, Erenumab, Were W...

SEATTLE, April 12, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced the appointment of Darren Cline to the Board of Directo...

SEATTLE, April 11, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, announced today that four Trudhesa ® (dihydroergotamine mesyla...

2023-03-24 15:20:02 ET Impel Pharmaceuticals Inc. (IMPL) Q4 2022 Earnings Conference Call March 24, 2023 08:30 ET Company Participants Adrian Adams - Chairman & Chief Executive Officer Leonard Paolillo - Chief Commercial Officer Rajiv Amin - Controller & ...

2023-03-24 08:27:18 ET Impel NeuroPharma press release ( NASDAQ: IMPL ): Q4 Non-GAAP EPS of -$0.97 beats by $0.06 . Revenue of $5.01M (+735.0% Y/Y) misses by $0.24M . As of December 31, 2022, Impel had approximately $60.7 million in cash and cash equivalents. T...

Trudhesa ® Achieved nTRx of Over 58.4K in 2022; nTRx Increased by 19.4% in Q4 vs. Q3 2022 Net Product Revenue Finished Year at $12.7 Million; Increased 62% in Q4 vs. Q3 2022 to $5 Million Impel to Host Investor Conference Call Today at 8:30 a.m. ET SEATTLE, March ...

SEATTLE, March 17, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced it will host a live webcast on Friday, March 24, 2...